<DOC>
	<DOCNO>NCT01066065</DOCNO>
	<brief_summary>The advent new antiretroviral drug improve management HIV naive patient term efficacy . However , long term metabolic profile drug yet compare association new antiretrovirals cardiovascular event remain controversial . Moreover , good tolerability easy dosage new drug might hypothetically influence adherence QOL HIV patient .</brief_summary>
	<brief_title>Metabolic Safety Raltegravir Versus Darunavir HIV Naive Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>VIH1 pregnancy previous Antiretroviral exposure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>cardiovascular disease</keyword>
	<keyword>HIV</keyword>
	<keyword>metabolic disorder</keyword>
	<keyword>HIV naive patient initiate HAART Raltegravir boost Darunavir</keyword>
</DOC>